IMMUNOGENICITY INDUCED BY TWO AND THREE DOSES OF THE BNT162B2 MRNA VACCINE IN PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES AND IMMUNOCOMPETENT CONTROLS: A LONGITUDINAL MULTI-CENTER STUDY

V. Furer,T. Eviatar,H. Peleg,D. Hagin, T. Freund,D. Levartovsky,D. Paran,I. Kaufman, A. Broyde,A. Polachek, O. Elalouf,J. Feld,A. Haddad,T. Gazitt,M. Elias, N. Hijaze,F. Kharouf,S. Gertel, S. Nevo, S. Pel,D. Zisman,O. Elkayam

Annals of the rheumatic diseases（2022）

引用 14|浏览7

暂无评分

摘要

The two-dose BNTb262 regimen was associated with similar clinical efficacy and similar waning of the humoral response over 6 months among patients with AIIRD and controls. The third vaccine dose restored the humoral response in all of the controls and the majority of patients.

查看译文

关键词

Autoimmune Diseases,Covid-19,Epidemiology,Rituximab,Vaccination

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要